The GLP‑1 story is starting to look bigger than appetite
A randomized Lancet trial found that semaglutide plus therapy reduced heavy drinking days in people with alcohol use disorder and obesity, adding momentum to the idea that GLP‑1 drugs may affect reward behavior as well as weight.
The most interesting GLP‑1 question is no longer just how much weight people lose. It is what else changes when a drug built for diabetes and obesity starts touching the brain systems that shape craving, reward, and habit.
A new randomized trial in The Lancet puts that question in unusually concrete terms. In people with moderate to severe alcohol use disorder and obesity, once-weekly semaglutide plus cognitive behavioral therapy reduced heavy drinking days more than placebo plus the same therapy over 26 weeks.
That does not make semaglutide an approved addiction medicine. It does make the GLP‑1 field harder to think about as a simple appetite story.
What the trial actually tested
The SEMALCO study was a 26-week, single-center, double-blind randomized trial. It enrolled 108 treatment-seeking adults with alcohol use disorder and obesity, then assigned them to either semaglutide 2.4 mg once weekly or placebo. Both groups also received standard cognitive behavioral therapy.
The primary endpoint was the change in heavy drinking days. In the semaglutide group, heavy drinking days fell by 41.1 percentage points from baseline. In the placebo group, they fell by 26.4 percentage points. The estimated treatment difference was 13.7 percentage points.
For a reader outside addiction medicine, the important translation is this: the control group also improved, probably because people were actively seeking treatment and receiving therapy. Semaglutide appeared to add something on top of that.
Why this matters beyond alcohol
The result lands in the middle of a broader pattern. Since the GLP‑1 drug boom began, clinicians and patients have reported changes that sound only partly related to hunger: less interest in alcohol, reduced compulsive snacking, quieter food noise, and in some cases shifts in other reward-driven behaviors.
Anecdotes alone are not evidence. But a randomized alcohol-use trial changes the conversation because it tests a specific behavioral outcome, not just body weight.
If the signal holds up, GLP‑1 drugs may become part of a larger category: metabolic drugs with psychiatric or behavioral effects. That would matter for medicine, because obesity, alcohol use disorder, diabetes, sleep, liver disease, and cardiovascular risk often cluster in the same people. A drug that moves more than one of those levers could change how clinicians think about treatment sequencing.
It would also matter commercially. The GLP‑1 market is already crowded around weight loss. If reward behavior becomes a serious development path, the next competition may not be only who produces the most weight loss, but who can prove meaningful benefits in conditions where craving and metabolic disease overlap.
The caution: this is not a general alcohol-craving answer yet
This is a promising trial, but it is still an early one.
It was single-center. It included 108 participants. Everyone had both alcohol use disorder and obesity. The intervention was semaglutide plus therapy, not semaglutide alone. And the trial does not answer whether the same effect would appear in people without obesity, in people not seeking treatment, or across different drinking patterns and psychiatric histories.
There is also a practical safety boundary. Semaglutide caused more gastrointestinal side effects, mostly mild to moderate and transient in the trial. That profile may be acceptable for some patients, but addiction treatment already struggles with adherence. A medication that works biologically still has to be tolerable enough for real people to keep using.
The bigger question now
The next test is replication: larger, multi-center trials that separate weight loss from reward effects, track relapse over longer periods, and compare semaglutide with existing alcohol-use-disorder medications rather than only placebo.
If those studies are negative, this may become another interesting GLP‑1 side story. If they are positive, the obesity-drug era will look less like a weight-loss revolution and more like the beginning of metabolic psychiatry.
Further reading
- Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity (The Lancet, PubMed): https://pubmed.ncbi.nlm.nih.gov/42070571/
- DOI: https://doi.org/10.1016/S0140-6736(26)00305-3
- SEMALCO trial record (ClinicalTrials.gov): https://clinicaltrials.gov/study/NCT05895643